HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
(Date:3/1/2015)... Viejo, California (PRWEB) March 01, 2015 ... announced a new transition pack for Final ... to add accordion style transitions to any FCPX editors ... “We’ve given our users the tools needed to easily ... media.” , The user gets many different controls over ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... Vancouver, BC (PRWEB) February 28, 2015 Vancouver ... several personal injury claims are affected by time limits. They ... can weaken a person’s claim or even nullify it. Many ... adverse effects on a client’s rights under BC law. As ... who are affected by accidents should consult a personal injury ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... its annual awards at the International Symposium on Malignant ... be held at the Hyatt Regency Bethesda in Bethesda, ... their dedicated work and commitment to the mission to ... Year Award will be presented to Miriam Ratner. Miriam ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
(Date:2/26/2015)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced that ... financial results after the market closes on Thursday, March ... will host a conference call with the investment community at ... 5, 2015 to discuss the results of the quarter ... the live conference call via telephone by dialing (877) 407-0784 ...
(Date:2/26/2015)... Feb. 26, 2015 Legislation passed today by ... provision to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA) of 2014 , ... Kevin Brady (R-TX) and Ranking Member Jim McDermott ... abuse epidemic and implement the right policies, said the ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
Cached News: